Skip to main content
HomeDrug Comparisons
Drug bottle and Pill

Compare Inpefa vs. Farxiga

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Inpefa (sotagliflozin) and Farxiga (dapagliflozin) are both medications used to help with heart-related issues and chronic kidney disease (CKD). They belong to a class of medications called sodium-glucose cotransporter (SGLT) inhibitors, but they work a bit differently. Inpefa is an SGLT1/SGLT2 inhibitor, which means it blocks sugar and sodium absorption in both the kidneys and the gut. Farxiga, on the other hand, is an SGLT2 inhibitor that works only in the kidneys. Inpefa is taken once daily before breakfast, while Farxiga can be taken once daily at any time of the day. Inpefa is not approved to treat diabetes directly, but it helps lower heart risks in people with Type 2 diabetes. Farxiga is approved to lower blood sugar in people with Type 2 diabetes and can be used by children 10 years and older. Inpefa is a newer medication without a generic version, while Farxiga has a cheaper generic available. Both medications can cause urinary tract infections, yeast infections, and increased urination, but Inpefa may also cause diarrhea. Both medications can interact with other diabetes medications, increasing the risk of low blood sugar.

  • Inpefa (sotagliflozin)
    Farxiga (dapagliflozin)
  • Inpefa (sotagliflozin)
    Farxiga (dapagliflozin)

  • Summary of Inpefa vs. Farxiga

    Summary for SGLT1/SGLT2 inhibitor
    Prescription only

    Inpefa (sotagliflozin) is a newer medication that's approved to lessen the risk of heart-related complications in people with heart failure and in people with Type 2 diabetes, chronic kidney disease (CKD), and other heart-related conditions. This medication comes as a tablet that you take by mouth once daily. Side effects can include urinary tract infections (UTIs) and diarrhea. Inpefa (sotagliflozin) is expected to be available in the U.S. in summer 2023.

    Summary for SGLT2 inhibitor
    Prescription only

    Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.

  • Indications of Inpefa vs. Farxiga

    Indications for
    •Lessen the risk of heart-related death and complications in adults with:
    •Heart failure, or
    •Type 2 diabetes, chronic kidney disease, and other heart-related risk factors
    Indications for
    •Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
    •Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
    •Lowering the risk of hospitalization and death due to heart problems in people with heart failure
    •Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)

  • Pros and Cons of Inpefa vs. Farxiga

    Pros and Const for SGLT1/SGLT2 inhibitor
    Pros
    •Taken just once a day
    •Can lower the risk of heart-related death, heart failure (HF) hospitalizations, and urgent HF visits by up to 33%
    •First-of-its-kind medication that blocks both SGLT1 and SGLT2 proteins
    Cons
    •Raises risk of UTIs and genital yeast infections
    •Newer medication, so there's no lower-cost generic version available yet
    •Unknown if safe or works well in people with severe kidney problems or are on dialysis
    Pros and Const for SGLT2 inhibitor
    Pros
    •Taken only once daily
    •Low risk of causing low blood sugar when taken by itself
    •Can take with other diabetes medications
    Cons
    •Raises risk of yeast infections and urinary tract infections (UTIs)
    •Not available as a liquid
    •Not recommended during the second and third trimesters of pregnancy

  • Common Side Effects of Inpefa vs. Farxiga

    Common Side Effects for
    •Urinary tract infection (9-12%)
    •Low fluid in the body (5-9%)
    •Diarrhea (7-8%)
    •Low blood sugar (4-8%)
    Common Side Effects for
    •Vaginal yeast infection in females (7-8%)
    •Nose and throat infection (6-7%)
    •Urinary tract infection (UTI, 4-6%)

  • Warnings of Inpefa vs. Farxiga

    Common Side Effects for
    •Ketoacidosis
    •Low fluids in the body (leading to low blood pressure or dehydration)
    •Genital and urinary tract infections
    •Low blood sugar when used with certain other diabetes medications
    Common Side Effects for
    •Ketoacidosis
    •Low fluids in the body (leading to low blood pressure or dehydration)
    •Genital and urinary tract infections
    •Low blood sugar (hypoglycemia) when used with other diabetes medications

  • Prices with our coupons for Inpefa vs. Farxiga

    Learn more about Inpefa
    Learn more about Farxiga

Compare other Heart Failure and Diabetes Type 2 drugs

Inpefa vs FarxigaInpefa vs JardianceBrenzavvy vs FarxigaBrenzavvy vs JardianceEntresto vs FarxigaEntresto vs JardianceFarxiga vs ActosFarxiga vs AfrezzaFarxiga vs GlucotrolFarxiga vs GlyburideFarxiga vs InvokanaFarxiga vs JardianceFarxiga vs KerendiaFarxiga vs MetforminFarxiga vs OzempicFarxiga vs RybelsusFarxiga vs WegovyGlucovance vs JardianceGlyxambi vs JardianceJanuvia vs FarxigaJanuvia vs JardianceJardiance vs ActosJardiance vs AfrezzaJardiance vs GlimepirideJardiance vs GlipizideJardiance vs GlucotrolJardiance vs GlyburideJardiance vs InvokametJardiance vs InvokanaSteglatro vs Farxiga
View More

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.